Birolini D, Moraes M F, de Souza O S
Rev Infect Dis. 1985 Nov-Dec;7 Suppl 4:S724-8. doi: 10.1093/clinids/7.supplement_4.s724.
Sixty-six patients with acute intraabdominal infections due to gram-negative aerobic organisms were treated with aztreonam plus clindamycin or with tobramycin plus clindamycin in a multicenter, comparative, randomized study. The patients had undergone a variety of surgical procedures; most of them had peritonitis. Thirty-three of the 36 patients in the aztreonam group and 26 of the 30 patients in the tobramycin group had satisfactory clinical responses. Only one gram-negative aerobic pathogen, a strain of Pseudomonas aeruginosa, persisted after treatment; the patient involved was in the tobramycin group. The incidences of adverse reactions, superinfections, and abnormal laboratory values were low in each treatment group. The difference between the efficacies of the two regimens was not statistically significant. This study suggests that aztreonam may be a useful alternative to the aminoglycosides in the treatment of gram-negative intraabdominal infections.
在一项多中心、比较性、随机研究中，66例由需氧革兰氏阴性菌引起急性腹腔内感染的患者，接受了氨曲南加克林霉素或妥布霉素加克林霉素的治疗。这些患者接受了各种外科手术；大多数患者患有腹膜炎。氨曲南组36例患者中的33例以及妥布霉素组30例患者中的26例有满意的临床反应。治疗后仅有一种需氧革兰氏阴性病原体——一株铜绿假单胞菌持续存在；相关患者在妥布霉素组。每个治疗组的不良反应、二重感染和实验室值异常的发生率都很低。两种治疗方案疗效的差异无统计学意义。本研究表明，在治疗革兰氏阴性腹腔内感染时，氨曲南可能是氨基糖苷类药物的一种有用替代药物。
